Patents by Inventor Glynis L. Kolling

Glynis L. Kolling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified bacterium
    Patent number: 9040302
    Abstract: Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive St. thermophilus bacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by the St. thermophilus bacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject a St. thermophilus bacterium modified to release a biotherapeutic agent following bile exposure. Administration of the St. thermophilus bacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders including C. difficile infection and antibiotic-associated diarrhea.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: May 26, 2015
    Assignees: North Carolina State University, University of Virginia Patent Foundation
    Inventors: Todd R. Klaenhammer, Richard L. Guerrant, Glynis L. Kolling, Evelyn Durmaz, Michael P. Timko, Cirle Alcantara Warren
  • COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC PEPTIDES
    Publication number: 20130259834
    Abstract: Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive St. thermophilus bacteria modified to release a biotherapeutic agent following bile exposure. Biotherapeutic agents released by the St. thermophilus bacteria disclosed herein include AQ and AQR rich peptides. Methods of the invention comprise administering to a subject a St. thermophilus bacterium modified to release a biotherapeutic agent following bile exposure. Administration of the St. thermophilus bacterium promotes a desired therapeutic response. The bacterium may be modified to express and release AQ or AQR rich peptides which subsequently inhibit cellular apoptosis or reduce mucosal damage. Thus, methods of the invention find use in treating or preventing a variety of gastrointestinal disorders including C. difficile infection and antibiotic-associated diarrhea.
    Type: Application
    Filed: May 19, 2011
    Publication date: October 3, 2013
    Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, NORTH CAROLINA STATE UNIVERSITY
    Inventors: Todd R. Klaenhammer, Richard L. Guerrant, Glynis L. Kolling, Evelyn Durmaz, Michael P. Timko, Cirle Alcantara Warren